| Name | Title | Contact Details |
|---|---|---|
Jan Pinkas |
Senior Vice President, Preclinical Research and Development and Chief Scientific Officer | Profile |
Derek Semmler |
Senior Director of IT, RandD | Profile |
Mark Lovell |
Senior Director, Head of Supply Chain | Profile |
Donna Regalado |
Director, HR Operations and Benefits | Profile |
Jitu Wadhane |
SVP Finance and Chief Accounting Officer | Profile |
Hawaii Bioenergy is a Honolulu, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rapid Micro Biosystems accelerates the detection of microbial contamination in the manufacture of pharmaceuticals, biologics, medical devices, and personal care products. The company`s Growth Direct™ Platform—the first and only growth-based platform to fully automate traditional microbial testing—detects contamination more quickly, delivering compelling economic benefits while improving quality control processes. The Growth Direct platform replaces slow, error-prone, manual processes, allowing manufacturers to accelerate timelines, maximize capacity, and reduce operational risk and downtime, all while maintaining the highest standards of data integrity. Rapid Micro Biosystems is dedicated to providing groundbreaking technology and products to support biomanufacturing companies in their mission to deliver the highest possible quality products for improved patient outcomes. Rapid Micro Biosystems is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Germany and the Netherlands.
KBI BioPharma is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Strategic Partnerships, LLC is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.